Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Reviving Your Life Sciences Deals Through Restructuring

Related Content

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab)

Join Us! The Future of Biotech Regulation Webinar

Third Circuit Affirms Rejection of AstraZeneca’s Challenges to IRA Drug Price Negotiation Program

President Trump Issues Two Executive Orders Concerning the Affordability and Accessibility of Drugs

Antitrust Life Sciences Quarterly Update 2025 Q1

Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy

Antitrust Life Sciences Quarterly Update 2025 Q1

Most Favored Nation Drug Pricing Executive Order Resurrects Prior President Trump Policy

Goodwin Represents Inozyme Pharma in $270 Million Acquisition by BioMarin to Strengthen Enzyme Therapy Business

Goodwin Scales Life Sciences Practice in Boston with the Arrival of Partner Felipe Heiderich

Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)

AI in Healthcare: Private Equity’s Next Frontier? (Real Deals)

Kronos Bio To Be Taken Private by Concentra Biosciences

Goodwin Welcomes Leading Life Sciences and Intellectual Property Partner William T. Christiansen II Ph.D.

Goodwin Guides Apnimed in Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor

Goodwin Guides Oak Hill Bio in Exclusive Licensing Agreement with Roche to Obtain Global Rights for a Treatment for Individuals with Angelman Syndrome

Life Sciences